注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
ABVC Biopharma Inc是一家专注于植物来源的药物和医疗器械开发的生物技术公司。该公司通过跟踪亚太地区研究机构的医学发现或医疗器械技术来开发产品线。其在研产品包括ABV-1501、ABV-1504、ABV-1505、ABV-1703、ABV-1601、ABV-1701和ABV-2002。ABV-1504是一种植物性再摄取抑制剂,靶向去甲肾上腺素治疗重度抑郁症 (MDD)。该公司正在开发用于治疗注意力缺陷多动障碍(ADHD)的ABV-1505。该公司开发了用于治疗癌症患者抑郁症的ABV-1601。ABV-1501是三阴性乳腺癌 (TNBC) 的联合疗法。ABV-1701是玻璃体切除术的玻璃体替代品。ABV-1703是一种用于晚期不可手术或转移性胰腺癌的药物。ABV-2002是一种角膜储存介质,由一种特殊的聚合物组成,用于保护眼组织免受渗透压影响。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Eugene Jiang | 37 | 2015 | Chairman & Chief Business Officer |
Norimi Sakamoto | 53 | 2017 | Independent Director |
Yen-Hsin Chou | 35 | 2017 | Independent Director |
Susanna Cunningham-Rundles | - | - | Member of Scientific Advisory Board |
Yoshinobu Odaira | 74 | 2019 | Independent Director |
Tsang Ming Jiang | 63 | 2017 | Director |
Chang-Jen Jiang | 67 | 2017 | Director |
Keith McBurnett | - | 2023 | Member of Scientific Advisory Board |
Thomas P. Laughren | - | 2023 | Member of Scientific Advisory Board |
Yu-Min Chung | 58 | 2022 | Independent Director |
Shuling Jiang | 67 | 2022 | Director |
Hsin-Hui Miao | 55 | 2022 | Independent Director |
Yih-Shiou Hwang | - | 2023 | Member of Scientific Advisory Board |
Maurizio Fava | - | 2023 | Member of Scientific Advisory Board |
Che-Wei Hsu | 42 | 2022 | Independent Director |
Tsung-Shann Jiang | 70 | 2019 | Chief Scientific Officer, Chief Strategy Officer & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核